• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Repare Therapeutics Inc. (Amendment)

    1/29/24 4:01:01 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RPTX alert in real time by email
    SC 13G/A 1 tm244117d22_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 2)*

     

    Repare Therapeutics Inc.

    (Name of Issuer)

     

    Common Shares, no par value

    (Title of Class of Securities)

     

    760273102

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    xRule 13d-1(b)
    ¨Rule 13d-1(c)
    ¨Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 760273102 13G Page 2 of 5 Pages 

     

    1. NAMES OF REPORTING PERSONS  
    ARK Investment Management LLC  
     
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
    (a) ¨  
    (b) ¨  
    3. SEC USE ONLY  
       
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
    Delaware, United States  
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER  
    2,821,560  
     
    6. SHARED VOTING POWER  
    0  
     
    7. SOLE DISPOSITIVE POWER  
    2,821,560  
     
    8. SHARED DISPOSITIVE POWER  
    0  
     
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
    2,821,560  
     
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  
    ¨  
     
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
    6.70%  
     
    12. TYPE OF REPORTING PERSON  
    IA  
     

     

     

     

     

    CUSIP No. 760273102 13G Page 3 of 5 Pages 

     

    Item 1(a) Name of issuer:

     

    Repare Therapeutics Inc.

     

    Item 1(b) Address of issuer's principal executive offices:

     

    7171 Frederick Banting, Suite 270, Building 2

    Saint-Laurent, Québec, Canada H4S 1Z9

     

    Item 2(a) Name of person filing:

     

    ARK Investment Management LLC

     

    Item 2(b) Address or principal business office or, if none, residence:

     

    ARK Investment Management LLC

    200 Central Avenue

    St. Petersburg, FL 33701

     

    Item 2(c) Citizenship:

     

    Delaware, United States

     

    Item 2(d) Title of class of securities:

     

    Common Shares, no par value

     

    Item 2(e) CUSIP No.:

     

    760273102

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

     

     

     

    CUSIP No. 760273102 13G Page 4 of 5 Pages 

     

    Item 4. Ownership

     

    (a)Amount beneficially owned:

     

    2,821,560

     

    (b)Percent of class:

     

    6.70%

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:  2,821,560

     

    (ii)Shared power to vote or to direct the vote:  0

     

    (iii)Sole power to dispose or to direct the disposition of:  2,821,560

     

    (iv)Shared power to dispose or to direct the disposition of:  0

     

    Item 5. Ownership of 5 Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

     

    To the knowledge of the Reporting Person, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, a number of the shares which represents more than five percent of the number of outstanding class of the shares.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

     

     

     

    CUSIP No. 760273102 13G Page 5 of 5 Pages 

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    The reporting persons agree that this statement is filed on behalf of each of them.

     

    Dated:    January 29, 2024

     

      ARK Investment Management LLC  
         
      By: /s/ Kellen Carter
        Name:  Kellen Carter
        Title:    Chief Compliance Officer

     

     

     

    Get the next $RPTX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RPTX

    DatePrice TargetRatingAnalyst
    6/9/2023$11.00 → $16.00Hold → Buy
    Stifel
    2/3/2023$28.00 → $15.00Overweight → Equal-Weight
    Morgan Stanley
    1/6/2023$28.00Overweight
    CapitalOne
    4/12/2022$11.00Buy → Hold
    Stifel
    3/17/2022$43.00Buy
    Goldman
    9/23/2021$48.00Buy
    Stifel
    9/13/2021$54.00Buy
    HC Wainwright & Co.
    8/16/2021$45.00 → $47.00Overweight
    Morgan Stanley
    More analyst ratings

    $RPTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Finance and CAO Alves Sandra Isabelle Barros was granted 4,100 shares, increasing direct ownership by 16% to 29,622 units (SEC Form 4)

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      4/29/25 5:07:34 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Alves Sandra Isabelle Barros claimed ownership of 25,522 shares (SEC Form 3)

      3 - Repare Therapeutics Inc. (0001808158) (Issuer)

      4/29/25 5:05:52 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by EVP, CHIEF FINANCIAL OFFICER Forte Steve

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      4/4/25 4:15:09 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

      Combines cancer biology, genetics, medicinal chemistry, and biologics research and development experience to rapidly advance a broad pipeline of preclinical oncology programs against genetically-defined cancers Licenses Repare's SNIPRx®, SNIPRx-surf, and STEP2 platforms for discovering druggable intracellular and synergistic cell-surface targets and identifying small molecules sensitive to specific cancer lesions Licenses preclinical small molecule and antibody programs for developing antibody drug conjugates Supported by DCx's co-founding investor, Amplitude Ventures, to create a leading company in developing differentiated first-in-class precision drug conjugates DCx Biotherapeut

      5/1/25 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

      Repare Therapeutics Inc. ("Repare") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced that it has out-licensed its discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation ("DCx"), a newly-launched Canadian biotechnology company developing next generation precision drug conjugates and supported by Amplitude Ventures. Additionally, DCx will retain certain preclinical research personnel, acquire lease rights to certain laboratory facilities in Montreal and acquire certain laboratory equipment. "We have taken careful steps to evaluate all aspects of our business to ensure continued value generation,

      5/1/25 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

      Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts for mini-oral presentation and the acceptance of four abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. Mini-Oral Presentation Details: Title: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656) Presenter: Alison M. Schram, MD, Memorial Sloan Kettering Cancer Center Session: Innovative Ap

      4/25/25 1:00:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Bvf Partners L P/Il bought $6,249,889 worth of shares (1,227,301 units at $5.09) (SEC Form 4)

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      11/17/23 4:54:43 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bvf Partners L P/Il bought $2,821,352 worth of shares (783,709 units at $3.60) (SEC Form 4)

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      11/3/23 5:37:44 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Repare Therapeutics upgraded by Stifel with a new price target

      Stifel upgraded Repare Therapeutics from Hold to Buy and set a new price target of $16.00 from $11.00 previously

      6/9/23 7:34:45 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Repare Therapeutics from Overweight to Equal-Weight and set a new price target of $15.00 from $28.00 previously

      2/3/23 7:35:18 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CapitalOne initiated coverage on Repare Therapeutics with a new price target

      CapitalOne initiated coverage of Repare Therapeutics with a rating of Overweight and set a new price target of $28.00

      1/6/23 8:30:21 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPTX
    SEC Filings

    See more
    • SEC Form 8-K filed by Repare Therapeutics Inc.

      8-K - Repare Therapeutics Inc. (0001808158) (Filer)

      6/20/25 4:05:25 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Repare Therapeutics Inc.

      8-K - Repare Therapeutics Inc. (0001808158) (Filer)

      6/17/25 4:05:34 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Repare Therapeutics Inc. filed SEC Form 8-K: Leadership Update

      8-K/A - Repare Therapeutics Inc. (0001808158) (Filer)

      6/2/25 4:13:02 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

      Phase 1 MYTHIC clinical trial of lunresertib in combination with camonsertib demonstrated a significant reduction in Grade 3 anemia and continued trends of patient response and benefit; FDA agrees with RP2D             First patient dosed in Phase 1 MYTHIC clinical trial of lunresertib in combination with the WEE1 inhibitor, Debio 0123; first clinical trial inhibiting both PKMYT1 and WEE1 Initiating Phase 2 TRESR expansion in ~20 patients evaluating monotherapy camonsertib in NSCLC; initial data expected in 2025 First patient dosed in Phase 1 LIONS monotherapy trial for PLK4 inhibitor RP-1664 Announced the appointment of Steven H. Stein, M.D. to Repare's Board of Directors, effecti

      5/7/24 4:05:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors

      Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company's upcoming annual meeting of shareholders in June 2024. The Company also announces that Todd Foley has decided not to stand for re-election as a director of the Company following the end of his current term as a Class I director on June 17, 2024, after serving more than seven years on the Board. "On behalf of the Company and our Board of Directors, we thank Todd for his dedication and partnership, which have played a crucial role in shaping Repare

      4/26/24 4:05:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones

      Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today provided a corporate update and highlighted key milestones anticipated in 2024. "We significantly advanced our pipeline in 2023 and presented strong data from key programs, notably for lunresertib in combination with camonsertib, and for camonsertib in combination with PARP inhibitors. In addition, we presented compelling preclinical data sets for RP-3467, which we're developing as a potential best-in-class Polθ inhibitor, and for RP-1664, a potential first- and best-in-class PLK4 inhibitor," said Lloyd M. Segal, President and Chief Executive Officer of Repare. "2

      1/8/24 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPTX
    Financials

    Live finance-specific insights

    See more
    • Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

      Combines cancer biology, genetics, medicinal chemistry, and biologics research and development experience to rapidly advance a broad pipeline of preclinical oncology programs against genetically-defined cancers Licenses Repare's SNIPRx®, SNIPRx-surf, and STEP2 platforms for discovering druggable intracellular and synergistic cell-surface targets and identifying small molecules sensitive to specific cancer lesions Licenses preclinical small molecule and antibody programs for developing antibody drug conjugates Supported by DCx's co-founding investor, Amplitude Ventures, to create a leading company in developing differentiated first-in-class precision drug conjugates DCx Biotherapeut

      5/1/25 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

      Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 weeks, comparing favorably to current standard of care Company plans to initiate a registrational Phase 3 trial of lunresertib in combination with camonsertib in endometrial cancer in 2H 2025 Repare to host conference call and webcast today at 4:30 p.m. ET to discuss these results Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today reporte

      12/12/24 4:20:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

      Event to be webcast live on Thursday, December 12 at 4:30 p.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib in combination with camonsertib at the recommended Phase 2 dose in an expansion cohort in patients with platinum-resistant ovarian and endometrial cancers harboring CCNE1 amplification or FBXW7 or PPP2R1A mutations, on Thursday, December 12, 2024 at 4:30 p.m. Eastern Time. Repare's executive management team will be joined by Brian Slomovitz, M.D.,

      12/10/24 4:05:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Repare Therapeutics Inc.

      SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

      11/14/24 9:00:57 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Repare Therapeutics Inc.

      SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

      11/14/24 5:05:19 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Repare Therapeutics Inc.

      SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

      11/14/24 9:42:55 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care